New York, NY -- (SBWIRE) -- 01/08/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Endeavour Silver Corp (NYSE:EXK), Synergy Pharmaceuticals Inc (NASDAQ:SGYP), Idenix Pharmaceuticals Inc (NASDAQ:IDIX), Harmony Gold Mining Co. (ADR) (NYSE:HMY)
Endeavour Silver Corp (NYSE:EXK) showed a volume of 1.35 million shares by the end of last trade whereas the average volume of the stock remained 1.25 million shares. The stock opened the session at $3.72 but then moved to $3.79. At that price, the stock showed a positive performance of 0.53%. Endeavour Silver Corp. (Endeavour) is engaged in the evaluation, acquisition, exploration, development and exploitation of silver mining properties in Mexico and in exploration in Chile. The Company’s producing mines include Guanacevi mine, Bolanitos Mine and El Cubo. The Guanacevi Mines Project and the Bolanitos Mines Project have been the primary focus of business activity. El Cubo is a producing silver-gold mine located in the southeast part of the historic Guanajuato mining district in central Mexico, only 10 kilometers from Endeavour's operating Bolanitos silver-gold mine in the northwest part of the Guanajuato district.
Will EXK Continue To Move Higher? Find Out Here
Synergy Pharmaceuticals Inc (NASDAQ:SGYP) opened the session at $5.45 and closed the session at $54.5. The stock showed a negative performance of -0.18% in previous trading session. Traded with volume of 1.34 million shares in the prior session and the average volume of the stock remained 594,933.00 shares. Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal (GI), disorders and diseases. The Company’s lead product candidate is plecanatide, a guanylyl cyclase C (GC-C), receptor agonist, to treat GI disorders, primarily chronic constipation (CC), and constipation-predominant-irritable bowel syndrome (IBS-C). It is also developing SP-333, the second generation GC-C receptor agonist for the treatment of gastrointestinal inflammatory diseases,
Has SGYP Found The Bottom And Ready To Gain Momentum? Find Out Here
Idenix Pharmaceuticals Inc (NASDAQ:IDIX) opened the session at $6.37 and closed the session at $6.60. The stock showed a positive performance of 4.27% in previous trading session. Traded with volume of 1.33million shares in the prior session and the average volume of the stock remained 1.02 million shares. The beta of the stock remained 0.44. Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. As of December 31, 2012, the Company's primary research and development focused on the treatment of patients with hepatitis C virus (HCV). In June 2012, the Company completed a three-day proof-of-concept study designed to evaluate 64 treatment-naive HCV genotype 1, 2, 3 or 4-infected patients. In July 2012, the FDA granted Fast Track designation for IDX719. The Company,
Why Should Investors Buy IDIX After The Recent Gain? Just Go Here and Find Out
Harmony Gold Mining Co. (ADR) (NYSE:HMY) the stock advanced 1.55% and finished the session at $2.62. Traded with volume of 1.32 million shares in the prior session and the average volume of the stock remained 2.80 million shares. The beta of the stock remained 0.12. Harmony Gold Mining Company Limited (Harmony) is engaged in conducting underground and surface gold mining and related activities, including exploration, processing and smelting. During the fiscal year ended June 30, 2012 (fiscal 2012), its mining operations reported total proven and probable reserves of 52.9 million ounces (including gold equivalent ounces), primarily from South African sources. During fiscal 2012, we processed 20.7 million tons of ore. During fiscal 2012, approximately 84% of its gold came from the Company’s South African underground mines,
Will HMY Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)